Comparison of Rivaroxaban and Warfarin for Treating Left Ventricular Blood Clots After Heart Attack in Nepal A Randomized Study at a Tertiary Cardiac Center

What this Trial Is About

This research aims to compare the effects of two blood-thinning medications, rivaroxaban and warfarin, in patients who develop a blood clot in the left ventricle of the heart after a heart attack. The study focuses on people who had a delayed hospital visit after their heart attack, a common issue in some regions, which increases the risk of such clots and related complications. The goal is to find out which medication better helps dissolve the clot and is safer to use. Participants will be randomly assigned to receive either rivaroxaban or warfarin. Those in the rivaroxaban group will take 15 to 20 mg doses depending on kidney function once daily with an evening meal. The warfarin group will start at 5 mg daily, adjusted to keep blood clotting levels within a target range, monitored by regular blood tests called INR. The study will last for three months, with follow-up visits scheduled to monitor treatment effects and any side effects. During the study, participants will undergo cardiac MRI scans to check if the blood clot has resolved after three months. Researchers will also monitor for major bleeding events and any embolic complications. Data will be securely collected and analyzed to assess the safety and effectiveness of both treatments. The study includes safety oversight by an independent board and plans to share findings through scientific publications and conferences.

Anticoagulation in Post MI LV Thrombus Trial in Nepal